How to use Easyhaler^®

Easyhaler^® Support Items

Easyhaler^® Patient Resources

Instructions for using your Easyhaler^®

Frequently asked Questions about Easyhaler^®

Easyhaler^® & Asthma Guidelines

Easyhaler^® Budesonide (budesonide)

Easyhaler^® Beclometasone (beclometasone dipropionate)

What is wehale.life

Easyhaler^® Product Family

Fobumix Easyhaler^® (budesonide / formoterol fumarate dihydrate)

Fusacomb Easyhaler^® (salmeterol xinafoate / fluticasone propionate)

Orion Pharma – DPI expert

What is MART?

(Maintenance and Reliever Therapy)?

Podcast: How to reduce the carbon footprint of inhalation therapy?

Highlights from Orion's webinar:

Sustainable care of asthma and COPD partnership between patients and professionals.

Insights from Doctor Omar Usmani

The ability of patients with asthma to achieve the correct inspiratory flow rates for different inhalers.

Easyhaler^®: A Carbon Neutral Inhaler Range¹

Optimal inspiratory flow

More asthma patients achieve the optimal inspiratory flow rate required for high-resistance inhalers than for low-resistance inhalers.

Carbon Footprint Assessment of Orion’s Dry Powder Inhalers

Clinical effectiveness of Fobumix Easyhaler^® (budesonide/formoterol fumarate dihydrate)

For patients with poorly controlled obstructive airway disease: a real-world study of patient-reported outcomes

Switching asthma and COPD patients to Fobumix Easyhaler^® (budesonide/formoterol fumarate dihydrate)

Leads to improved clinical outcomes and quality of life in real-world clinical practice

Costs of switching to low global warming potential inhalers

Internal resistance of an Easyhaler device - a technical summary

Cost saving of switching to equivalent inhalers and its effect on health outcomes.

Webinars